Improvements to the U.S. supply chain are needed to reduce shortages and protect American patients. Industry, academia, ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

QurAlis’ Kasper Roet describes the regulatory hurdles facing the RNA research space in the U.S. and why many companies are pursuing clinical work elsewhere.

QurAlis founder Kasper Roet explains how precision medicine can revolutionize neurogenerative disease therapeutics.

Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional ...

On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

Artificial intelligence is revolutionizing the life sciences industry by driving innovation in various domains, such as drug discovery, clinical trials, and regulatory compliance. While AI offers the ...

With the recent sign-off from the FDA on protocols for a pivotal Phase 3 trial of IMNN-001 in advanced ovarian cancer, Imunon is poised to bring its IL-12 DNA plasmid vector (encased in a nanoparticle ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...